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Abstract: Age-related changes in splice-forms of LMNA, which encodes the nuclear lamina proteins lamin A/C, 
have not been investigated in skeletal muscle. In the rare premature ageing disease, Hutchinson-Gilford progeria 
syndrome (HGPS), de novo point mutations in LMNA activate a cryptic splice site in exon 11, resulting in a 150 base 
deletion in LMNA mRNA and accumulation of a truncated protein isoform, progerin. The LMNA ∆150 progerin tran-
script has also been found in trace quantities in tissues of healthy people and its implication in ‘natural’ ageing has 
been proposed. We therefore investigated the expression of progerin and lamin A/C in normal human and mouse 
skeletal muscles of different ages. LMNA ∆150 was detected in most muscle samples from healthy individuals aged 
16-71 years, but was not present in any mouse muscle samples up to the age of 18 months. Real time qPCR of hu-
man muscle samples showed that there was an age-related increase in both the full length lamin A and LMNA ∆150 
transcripts, whereas their protein levels did not change significantly with age. These findings indicate that there is a 
basal level of mis-splicing during LMNA expression that does not change with ageing in human muscle, but at levels 
that do not result in increased aberrant protein. The significance of these findings in the pathophysiology of muscle 
ageing is uncertain and warrants further investigation.
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Introduction
The LMNA gene encodes the nuclear lamina 
proteins, lamin A and C, through alternative 
splicing involving exon 10 and terminal exon 
usage. Apart from providing mechanical sup-
port to maintain nuclear shape, the lamina net-
work has a number of other roles, such as inter-
acting with heterochromatin to localize it to the 
periphery of the nucleus [1], controlling mitosis 
through interaction with cell division regulators 
[2], and being involved in initiation of DNA repli-
cation and transcription [3, 4]. Mutations in 
LMNA are associated with a heterogeneous 
group of disorders, collectively known as the 
‘laminopathies’, which include the premature 
ageing disease Hutchinson-Gilford Progeria 
Syndrome (HGPS), a number of different forms 
of muscular dystrophy, Charcot-Marie-Tooth dis-
ease type 2B1, Dunnigan-type familial partial 
lipodystrophy, and mandibuloacral dysplasia [5, 
6]. Most patients with HGPS carry a heterozy-
gous de novo synonymous substitution in LMNA 
(1824C>T, G608G) that activates a nearby cryp-
tic donor splice site within exon 11, resulting in 
the production of an internally truncated LMNA 
mRNA missing 150 bases (LMNA ∆150) [7, 8]. 
It is uncertain how the encoded protein ‘proger-
in’ causes accelerated tissue ageing, but the de 
novo dominant mode of inheritance and the fail-
ure to rescue the phenotype by increasing wild-
type lamin A expression suggests a dominant-
negative effect [9].  
Progerin is also present in trace amounts in 
some normal tissues such as skin, liver, heart 
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and blood vessels, and it has been suggested 
that its accumulation may play a role in the nor-
mal ageing process in these tissues [10, 11]. 
However, previous studies have not investigat-
ed the expression of progerin in skeletal mus-
cle, and it remains unproven whether progerin 
expression in normal tissues is age-related or 
contributes to cellular ageing.
In this study we investigated the changes in 
LMNA splicing and expression of the different 
isoforms in human and mouse skeletal muscle 
using RT-PCR, real-time qPCR, immunoblotting 
and confocal microscopy, and we compared the 




Tissue samples from the vastus lateralis mus-
cle were obtained from otherwise healthy indi-
viduals, aged 16 to 71 years (n=18, 10 male), 
undergoing evaluation for malignant hyperther-
mia (MH) susceptibility. All these individuals 
were subsequently classified as MH-negative 
after in vitro contracture testing. Surplus mate-
rial from muscle biopsies was stored in the 
Department of Anatomical Pathology at Royal 
Perth Hospital and was provided after informed 
consent. All biopsies showed normal muscle 
histology.
Muscle samples were also obtained from the 
triceps brachii, quadriceps femoris and tibialis 
anterior muscles of wild-type C57BL6/SJL mice 
aged 6, 9, 12 and 18 months (n=13, 9 males). 
Additional heart and liver tissues were obtained 
from the same mouse colony of the same age 
range (n=8, 6 males). Tissues were snap-frozen 
in isopentane chilled with liquid nitrogen. All 
muscle samples were stored at -80°C before 
use. Sections 8 μm thick for immunohistologi-
cal studies and immunoblotting were cut using 
a Leica CM1900 cryostat (Leica Microsystems, 
North Ryde, Australia).
Primary HGPS fibroblasts were obtained from 
Coriell cell repositories (Coriell Institute for 
Medical Research, Camden, NJ, Cat # 
AG03513). Cells were proliferated in Dulbecco’s 
Modified Eagle Medium (Gibco, Mulgrave, 
Australia) supplemented with 15% fetal calf 
serum, 10 U/ml penicillin, 10 mg/ml streptomy-
cin, and 250 ng/ml Amphotericin B (Sigma 
Aldrich, Sydney, Australia) in a 37°C incubator 
with 5% CO2.
RNA extraction and reverse-transcription poly-
merase chain analysis (RT-PCR)
RNA was extracted from HGPS fibroblast cul-
tures, human muscle specimens, and muscle, 
heart and liver tissues from wild-type mice, 
using Trizol (Invitrogen, Mulgrave, Australia) 
according to the manufacturer’s instructions. 
RNA pellets were resuspended in RNase-free 
water and purity and concentration estimated 
from absorbance reading using a Nano-drop 
spectrophotometer (Thermo Scientific, Score- 
sby, Australia).
100 ng of total RNA was used as template in a 
one-step RT-PCR with Superscript III (Invitrogen), 
using human specific primers located in exons 
7 and 12, or murine specific primers annealing 
to the exon 9/10 junction and exon 12 for 
detection of both LMNA and LMNA ∆150 tran-
scripts (Table 1). Reverse transcriptase-amplifi-
cation reactions were incubated in a G-Storm 
GS1 thermocycler (GeneWorks, Hindmarsh, 
Australia) using the following conditions: 55°C 
for 30 min, 95°C for 10 min, 35 cycles of 94°C 
for 30 sec, 60°C for 1 min, 68°C for 2 min. 
Amplicons were separated on 2% agarose gels 
and, after staining with ethidium bromide, 
images were captured using the Chemi-Smart 
3000 gel documentation system (Vilber Lour- 
mat, Marne-la-Vallée, France).
Real time polymerase chain analysis (qRT-
PCR)
TaqMan qRT-PCR assays (TaqMan, Mulgrave, 
Australia) were used to detect LMNA, LMNA 
Table 1. Primers for RT-PCR
Species Primer sequences (5’→3’)
Human AACTGGAGTCCACTGAGA Ex7 forward
AGATTACATGATGCTGCAGTT Ex12 reverse
Mouse ATCAACTCCACTGGAGAAGAAGT Ex9/10 forward
CAGACAGGAGGTGGCATGT Ex12 reverse
Ethical approval for the studies was obtained 
from the Royal Perth Hospital Human Re- 
search Ethics Committee and the University 
of Western Australia Animal Experimentation 
Committee.
Cell culture
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∆150 and LMNC transcripts [11]. A commer-
cially available assay (Applied Biosystems, 
Mulgrave, Australia) targeting human RPLP0, 
was included as an endogenous control. RNA 
was reverse-transcribed using the Superscript 
II cDNA synthesis kit (Invitrogen) with 50 ng ran-
dom hexamers. Ten μl real-time reactions with 
5 μl of TaqMan Universal Master Mix were per-
formed in MicroAmp 384-well plate in the 
7900HT Real-Time PCR system (Applied 
Biosystems). To increase the detection capabil-
ity, 4.8 μl cDNA was used for LMNA ∆150 reac-
tions and 2.5 μl for LMNA and RPLP0 reactions. 
For LMNA ∆150 assays: 200 nM MGB probe, 
50 nM forward primer and 100 nM reverse 
primer were used, whereas for LMNA and 
LMNC assays: 200 nM MGB probe, 500 nM for-
ward primer and 500 nM reverse primer were 
used [11]. Reactions were carried out in tripli-
cate and end-point products were fractionated 
on 2% agarose gels and sequenced to confirm 
amplicon identities.
Standard curves for all three transcripts were 
obtained by diluting cDNA, prepared from RNA 
extracted from cultured HGPS fibroblasts. The 
detectable range was over a 5-log dilution, and 
the efficiencies were calculated to be 102.9%, 
97.8%, 102.0% and 91.4% for LMNA ∆150, 
LMNA, LMNC and RPLP0, respectively.
Western blots
Western blotting was performed based on the 
protocols of Cooper et al [12]. Muscle tissues 
(10 mg) from 12 normal individuals were cryo-
sectioned and suspended in 200 μl treatment 
buffer containing 125 mM Tris-HCl (pH 6.8), 
15% SDS (w/v), 10% glycerol (v/v), 0.5 mM 
phenylmethylsulfonyl fluoride and 9 μl protease 
inhibitor cocktail (Sigma Aldrich). After sonica-
tion, 6 pulses of 1 sec duration at a setting of 
30/100 on the Sonics sonicator (Sonics, 
Newtown, CT), the homogenates were stored at 
-80°C. The samples were reduced by adding 
dithiothreitol to a final concentration of 50 mM 
and mixed with 0.4 μg/ml bromophenol blue 
before use. The protein extracts were incubat-
ed at 95°C for 5 min and centrifuged at 14,000 
rpm for 5 min. Protein extracts (15 μl) were 
separated on NuPAGE 4-12% Bis-Tris gels (Life 
Technologies, Mulgrave, Australia) and electro-
transferred to polyvinylidene fluoride mem-
branes (Pall, Melbourne, Australia). After 
immersion in 5% skim milk blocking solution for 
30 min, membranes were incubated with pri-
mary antibodies (anti-lamin A/C polyclonal, 
Santa Cruz, Dallas, TX, 1:100; anti-lamin B2, 
Santa Cruz, 1:100) overnight at 4°C. After sub-
sequent washing, membranes were incubated 
with with HRP labeled goat anti rabbit immuno-
globulins (Dako, 1:2,000) for 1 hr and incubat-
ed with chemiluminescent substrate for 5 min. 
Images were captured by a Chemi-Smart 3000 
gel documentation system (Vilber Lourmat) 
using Chemi-capt software and image analysis 
was performed using Bio-1D software.
Confocal microscopy
Immunohistochemistry for progerin was per-
formed on human muscle sections (n=6, 16 to 
70 yr) and HGPS fibroblast cultures. Briefly, 
endogenous peroxidase was blocked in 1% 
(v/v) H2O2 in methanol, followed by incubation 
with a specific anti-progerin antibody (Abcam, 
Sapphire Bioscience, Waterloo, Australia, 1:50) 
overnight at 4°C. After washing by PBS, sec-
Figure 1. High sensitivity RT-PCR clearly indicated the presence of the LMNA ∆150 transcript in most normal human 
skeletal muscle.
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tions and cultures were incubated with Alexor 
Fluor 488 goat anti-mouse immunoglobulin 
(Invitrogen, 1:400) for 1 hr at room tempera-
ture, and then counterstained with Hoechst 
33342 (Sigma Aldrich, 1:4,000) for 5 min. After 
rinsing with PBS, slides were viewed under a 
Nikon A1Si laser scanning confocal microscope 
(Coherent Scientific, Hilton, Australia).
Data analysis
Data were analyzed by the Sequence Detector 
System (SDS) software 1.3.1 (Applied Bio- 
systems). A standard curve analysis method 
was used to calculate the fold difference 
between samples and the calibrator sample 
(normal 25 years old). Linear regression was 
used to test the correlation between age and 
the levels of LMNA, LMNC and LMNA ∆150 
transcripts, and the LMNA/LMNA ∆150 and 
LMNA/LMNC ratios. Independent t test was 
used to test the difference in LMNA ∆150 and 
LMNA levels between males and females. P val-
ues <0.05 were considered statistically 
significant.
Results
RT-PCR of human muscle
An amplicon representing the LMNA transcript 
was ubiquitously detected in human samples 
by RT-PCR. Upon increasing amplification sensi-
tivity to detect less abundant transcripts, an 
Figure 2. Relative quantification analysis by qRT-PCR. Samples with threshold cycle (Ct) numbers that fell outside 
the dynamic range of the assays were excluded from the analysis. As a result, 14, 16 and 13 normal samples were 
used for analysis of LMNA, LMNA ∆150, LMNC levels respectively. There is an age-dependent increase of wild-type 
LMNA (A) and LMNA ∆150 (B), but not LMNC (C), transcript levels in human skeletal muscle biopsies. The youngest 
sample in the qRT-PCR study (25 yr old) was used as the calibrator sample.
Figure 3. Lamin A and C proteins are readily demonstrated in extracts from all muscle samples. Trace amounts of 
progerin in normal human muscle are detected in all samples as well. HGPS fibroblast cultures were included as a 
positive control for progerin. Probed with Santa Cruz polyclonal anti-lamin A/C antibody. 
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amplicon 150 bp smaller than the expected full 
length LMNA product was also detected in 
most of the human muscle samples (Figure 1). 
DNA sequencing confirmed this shorter ampli-
con to represent the LMNA ∆150 transcript.
qRT-PCR analysis of human muscle
Quantitative real time-PCR analyses employing 
validated assays specific for LMNA, LMNA 
∆150, LMNC, and RPLP0 transcripts were 
undertaken [11]. There was a moderate corre-
lation between age and levels of both LMNA 
(r2=0.624, p<0.0001) and LMNA ∆150 
(r2=0.593, p=0.001) in the human muscle sam-
ples (Figure 2A, 2B). There was a subtle 
decrease in the ratio of LMNA/LMNA ∆150 
transcripts, although the statistical significance 
of this trend is limited by the number of sam-
ples at each time point available for evaluation 
(r2=0.565, p=0.035), In contrast, no correla-
tion was found between age and LMNC levels 
(Figure 2C) or LMNA/LMNC ratios (p=0.244, 
0.088, r2=0.02, 0.241). The LMNA level was 
900 to 2,400 times that of LMNA ∆150 (1,200 
times on average). There was no significant dif-
ference in LMNA ∆150 or LMNA levels between 
male and female muscle samples (p=0.866, 
0.221). Based upon the qPCR data, the level of 
progerin transcript in the human muscle sam-
ples was estimated to be 150-1400 times 
lower than that detected in HGPS fibroblasts.
Detection of progerin protein
Western blotting of protein extracts from the 
HGPS cells readily demonstrated the presence 
of all three target proteins, lamin A, progerin 
and lamin C, when probed with the lamin A/C 
antibody (Figure 3). A faint progerin band was 
also detected in all of the human muscle sam-
ples. Although low levels of progerin could be 
detected in most samples, there was consider-
able variation between individuals. Densito- 
metry analysis did not show any significant cor-
relation between age and progerin or lamin A 
levels, or lamin A/progerin ratios as in the tran-
script studies (results not shown).
Figure 4. Immunohistochemistry probed with progerin specific antibody. A proportion of HGPS fibroblasts 
demonstrated immunoreactivity for progerin (A-C). Muscle sections from a 68 yr normal individual did not show any 
progerin-positive nuclei (D-F).
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Immunohistochemistry
Immunohistochemistry employing the progerin 
specific antibody [13] did not show any progerin 
positive staining myonuclei in human muscle 
sections (0/6,054 nuclei counted), whereas 
25.4% of HGPS fibroblast nuclei (26/95) were 
positive for progerin on confocal microscopy 
(Figure 4). This indicates that progerin detected 
in normal skeletal muscle is diffusely expressed 
at very low levels, rather than being concentrat-
ed in a few myonuclei.
Mouse muscle studies 
Although Lmna was consistently found in all 
mouse muscle samples, no Lmna ∆150 bands 
were detected in any of the murine samples, 
even after increasing the rounds of PCR to en- 
hance sensitivity (Figure 5). Aged mouse heart 
and liver tissues were also assessed for proger-
in expression to ascertain if inappropriate 
Lmna splicing occurs in these murine tissues. 
As in murine muscle, no Lmna ∆150 amplicon 
was generated from RNA extracted from the 
heart or liver (data not shown). Since the Lmna 
∆150 transcript could not be detected, immu-
noblotting for progerin was not performed.
Discussion
This study investigated the changes in expres-
sion of LMNA in skeletal muscle obtained from 
individuals aged between 16 to 71 years. There 
appears to be an age-related increase in ex- 
pression of the full length lamin A transcript. 
The increase in the progerin transcript is in line 
with the elevated LMNA expression and corre-
sponds with elevated transcription rather than 
an increase in splicing errors in human skeletal 
muscle. The age-dependent increase in proger-
in transcript in muscle samples does not trans-
late into increased accumulation the progerin 
protein in older individuals. Although extremely 
low levels of progerin could be detected in the 
majority of samples, there was considerable 
variation in progerin levels between individuals 
when compared to lamin A/C. This work is con-
sistent with previous studies in more rapidly 
dividing tissues such as skin and liver, in which 
no obvious correlation was found between age 
and the levels of LMNA ∆150 or progerin pro-
tein [10, 14].
Progerin is generated through inappropriate 
alternative splicing of LMNA exon 11, and is 50 
amino acids shorter than the normal lamin A. 
The deleted domain includes an endoproteo-
lytic site for post-translational modification of 
prelamin A, the precursor of lamin A [15]. As a 
result, instead of the last 18 amino acids being 
cleaved as normally occurs, progerin retains a 
farnesyl and a methyl group in the carboxyl ter-
minal and the truncated protein remains per-
manently inserted into the nuclear lamina [16]. 
During mitosis, phosphorylation of lamin A 
Figure 5. Lmna transcript (481 bases) was present in mouse muscle, but the Lmna ∆150 product was not detected 
using highly sensitive RT-PCR conditions. Several smaller bands were sporadically amplified and DNA sequencing 
indicated these to be RT-PCR artifacts.
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causes it to separate from the nuclear mem-
brane and become soluble in the cytosol [17]. 
In contrast, progerin fails to dissociate from the 
nuclear membrane, interfering with normal 
nuclear splitting and resulting in dysmorphic 
nuclear shapes. In dividing cells, nuclei contain-
ing excessive progerin show dramatically 
reduced lamin A foci in the nucleoplasm and 
segregation of chromosomes during mitosis 
[18]. The Notch cell fate determination pathway 
and the p53 tumour suppression pathway are 
both activated in progerin-overexpressing cells 
as well as in a HGPS mouse model [10, 19, 20], 
suggesting that progerin can also interfere with 
cell differentiation. Although muscle weakness 
is not a prominent symptom of HGPS, impaired 
muscle function has been noted in affected 
individuals and in a mouse model of HGPS [21, 
22]. In accordance with these findings, tran-
scriptome studies have shown altered gene 
expression, particularly in tissues of mesoder-
mal origin [23], including genes involved in 
muscle development, differentiation and mus-
cle contraction (MEOX2, EYA2, ACTA2).
Our finding that lamin A transcript levels 
increase with age in human skeletal muscles is 
in accord with the finding of Wegner et al., who 
reported that LMNA transcript levels were high-
er in older human muscles [24], and proposed 
that this may represent a compensatory mech-
anism for deteriorating nuclear function in mus-
cle with ageing [25]. Whether the associated 
up-regulation of the alternatively spliced 
progerin isoform further exacerbates the 
effects of ageing is uncertain. Since the incre-
ment trends are very similar between LMNA 
and LMNA ∆150 transcripts, it does not appear 
likely that splicing errors increase with age in 
human skeletal muscle. The variable progerin 
levels in different individuals may reflect differ-
ences in their genetic background and splicing 
machinery. In addition to the 150-1400x differ-
ence in LMNA ∆150 levels between normal 
muscle and HGPS fibroblasts, a similar fold dif-
ference (110-1200) was also demonstrated 
when digital droplet PCR [26] was used to ana-
lyze progerin transcript levels (data not shown).
In contrast to human muscle, we did not detect 
progerin transcripts in mouse skeletal muscles 
up to 18 months of age, or in other murine tis-
sues such as liver and heart. In a separate 
study, we were unable to induce expression of 
Lmna ∆150 in mouse myoblast cultures using 
splice switching antisense oligomers (unpub-
lished data), whereas this splice switching was 
readily achieved in human muscle cultures 
(manuscript in preparation). We hypothesize 
that these results suggest that the processing 
of murine Lmna pre-mRNA is more robust and 
less prone to splicing errors than the human 
equivalent. An in silico evaluation of the splice 
strength for the wild-type donor splice site 
(lamin A) and the alternative splice site (proger-
in) showed that they are identical in the human 
and the mouse (http://www.umd.be/HSF/). 
Nevertheless, splicing requires more than the 
donor or acceptor splice sites and prediction of 
exonic splicing enhancers (ESEs) in human and 
mouse exon 11 shows several different poten-
tial binding sites for splicing factors, such as 
the lack of putative binding motifs for serine/
arginine splicing factor 6 around the alternative 
splice site in the mouse Lmna exon 11 (data 
not shown, http://rulai.cshl.edu/cgibin/tools/
ESE3/esefinder.cgi). Hence the differences in 
lamin A/C splicing found in human and mouse 
muscle may be due to the presence of different 
ESEs that strengthen the recognition of the 
normal mouse Lmna exon 11 donor site, and/
or silencers that weaken selection of the alter-
native cryptic donor splice site.
Conclusions
In conclusion, our findings indicate that there is 
increased expression of LMNA in human skel-
etal muscle, presumably through increased 
transcription, and this leads to a corresponding 
increase in the LMNA ∆150 progerin transcript. 
Nevertheless, levels of the progerin transcript 
are extremely low and are not translated into a 
corresponding increase in the protein. Usage of 
the HGPS cryptic splice site in LMNA exon 11 
with ageing reflects a background splicing error, 
which does not increase with age and only 
trace quantities of progerin protein accumu-
late. Further studies are required to determine 
the significance of these findings in the ageing 
process in skeletal muscle.
Acknowledgements
The authors thank Dr Gisèle Bonne for her help-
ful discussions and advice, and Ms Abbie 
Adams for technical support with the animal 
work. This work was supported by the Neuro- 
muscular Foundation of Western Australia. Dr 
Yue-Bei Luo was supported by a China Scholar- 
Progerin in skeletal muscle
2785 Int J Clin Exp Pathol 2013;6(12):2778-2786
ship Council-University of Western Australia 
joint PhD scholarship. Dr Chalermchai Mitrpant 
was partly supported by a Chalermphrakiat 
grant, Faculty of Medicine, Siriraj Hospital, 
Mahidol University.
Disclosure of conflict of interest
None.
Address correspondence to: Dr. Steve D Wilton, 
Centre for Comparative Genomics, Murdoch 
University, 90 South Street, Murdoch, Western 
Australia, Australia, 6150. Tel: + 61 8 9360 2305; 
Fax: + 61 8 93607238; E-mail: swilton@ccg.mur-
doch.edu.au
References
[1] Mounkes LC, Burke B and Stewart CL. The A-
type lamins: nuclear structural proteins as a 
focus for muscular dystrophy and cardiovascu-
lar diseases. Trends Cardiovasc Med 2001; 
11: 280-285.
[2] Boban M, Braun J and Foisner R. Lamins: 
‘structure goes cycling’. Biochem Soc T 2010; 
38: 301-306.
[3] Kennedy BK, Barbie DA, Classon M, Dyson N 
and Harlow E. Nuclear organization of DNA 
replication in primary mammalian cells. Genes 
Dev 2000; 14: 2855-2868.
[4] Kumaran RI, Muralikrishna B and Parnaik VK. 
Lamin A/C speckles mediate spatial organiza-
tion of splicing factor compartments and RNA 
polymerase II transcription. J Cell Biol 2002; 
159: 783-793.
[5] Broers JL, Ramaekers FC, Bonne G, Yaou RB 
and Hutchison CJ. Nuclear lamins: laminopa-
thies and their role in premature ageing. Physi-
ol Rev 2006; 86: 967-1008.
[6] Quijano-Roy S, Mbieleu B, Bonnemann CG, 
Jeannet PY, Colomer J, Clarke NF, Cuisset JM, 
Roper H, De Meirleir L, D’Amico A, Ben Yaou R, 
Nascimento A, Barois A, Demay L, Bertini E, 
Ferreiro A, Sewry CA, Romero NB, Ryan M, 
Muntoni F, Guicheney P, Richard P, Bonne G 
and Estournet B. De novo LMNA mutations 
cause a new form of congenital muscular dys-
trophy. Ann Neurol 2008; 64: 177-186.
[7] Reddel CJ. Lamin A expression levels are un-
perturbed at the normal and mutant alleles 
but display partial splice site selection in 
Hutchinson-Gilford progeria syndrome. J Med 
Genet 2004; 41: 715-717.
[8] Eriksson M, Brown WT, Gordon LB, Glynn MW, 
Singer J, Scott L, Erdos MR, Robbins CM, Mo-
ses TY, Berglund P, Dutra A, Pak E, Durkin S, 
Csoka AB, Boehnke M, Glover TW and Collins 
FS. Recurrent de novo point mutations in lamin 
A cause Hutchinson-Gilford progeria syndrome. 
Nature 2003; 423: 293-298.
[9] Scaffidi P and Misteli T. Reversal of the cellular 
phenotype in the premature aging disease 
Hutchinson-Gilford progeria syndrome. Nat 
Med 2005; 11: 440-445.
[10] Scaffidi P and Misteli T. Lamin A-dependent 
nuclear defects in human aging. Science 
2006; 312: 1059-1063.
[11] Rodriguez S, Coppedè F, Sagelius H and Eriks-
son M. Increased expression of the Hutchin-
son-Gilford progeria syndrome truncated lamin 
A transcript during cell aging. Eur J Hum Genet 
2009; 17: 928-937.
[12] Cooper ST, Lo HP and North KN. Single section 
Western blot: improving the molecular diagno-
sis of the muscular dystrophies. Neurology 
2003; 61: 93-97.
[13] Liu GH, Barkho BZ, Ruiz S, Diep D, Qu J, Yang 
SL, Panopoulos AD, Suzuki K, Kurian L, Walsh 
C, Thompson J, Boue S, Fung HL, Sancho-Mar-
tinez I, Zhang K, Yates J 3rd and Izpisua Bel-
monte JC. Recapitulation of premature ageing 
with iPSCs from Hutchinson-Gilford progeria 
syndrome. Nature 2011; 472: 221-225.
[14] McClintock D, Ratner D, Lokuge M, Owens DM, 
Gordon L, Collins FS and Djabali K. The mutant 
form of lamin A that causes Hutchinson- Gil-
ford progeria is a biomarker of cellular aging in 
human skin. PLoS One 2007; 2: e1269.
[15] Davies BSJ, Fong LG, Yang SH, Coffinier C and 
Young SG. The posttranslational processing of 
prelamin A and disease. Annu Rev Genom 
Hum G 2009; 10: 153-174.
[16] Yang SH. Blocking protein farnesyltransferase 
improves nuclear blebbing in mouse fibro-
blasts with a targeted Hutchinson-Gilford pro-
geria syndrome mutation. Proc Natl Acad Sci U 
S A 2005; 102: 10291-10296.
[17] Gerace L and Blobel G. The nuclear envelope 
lamina is reversibly depolymerized during mi-
tosis. Cell 1980; 19: 277-287.
[18] Cao K, Capell BC, Erdos MR, Djabali K and Col-
lins FS. A lamin A protein isoform overex-
pressed in Hutchinson-Gilford progeria syn-
drome interferes with mitosis in progeria and 
normal cells. Proc Natl Acad Sci U S A 2007; 
104: 4949-4954.
[19] Scaffidi P and Misteli T. Lamin A-dependent 
misregulation of adult stem cells associated 
with accelerated ageing. Nat Cell Biol 2008; 
10: 452-459.
[20] Varela I, Cadiñanos J, Pendás AM, Gutiérrez-
Fernández A, Folgueras AR, Sánchez LM, Zhou 
Z, Rodríguez FJ, Stewart CL, Vega JA, Tryggva-
son K, Freije JM and López-Otín C. Accelerated 
ageing in mice deficient in Zmpste24 protease 
is linked to p53 signalling activation. Nature 
2005; 437: 564-568.
Progerin in skeletal muscle
2786 Int J Clin Exp Pathol 2013;6(12):2778-2786
[21] Merideth MA, Gordon LB, Clauss S, Sachdev V, 
Smith AC, Perry MB, Brewer CC, Zalewski C, 
Kim HJ, Solomon B, Brooks BP, Gerber LH, 
Turner ML, Domingo DL, Hart TC, Graf J, Reyn-
olds JC, Gropman A, Yanovski JA, Gerhard-Her-
man M, Collins FS, Nabel EG, Cannon RO 3rd, 
Gahl WA and Introne WJ. Phenotype and 
course of Hutchinson-Gilford progeria syn-
drome. N Engl J Med 2008; 358: 592-604.
[22] Greising SM, Call JA, Lund TC, Blazar BR, Tolar 
J and Lowe DA. Skeletal muscle contractile 
function and neuromuscular performance in 
Zmpste24 (-/-) mice, a murine model of human 
progeria. Age (Dordr) 2012; 34: 805-19.
[23] Csoka AB, English SB, Simkevich CP, Ginzinger 
DG, Butte AJ, Schatten GP, Rothman FG and 
Sedivy JM. Genome-scale expression profiling 
of Hutchinson-Gilford progeria syndrome re-
veals widespread transcriptional misregula-
tion leading to mesodermal/mesenchymal de-
fects and accelerated atherosclerosis. Aging 
Cell 2004; 3: 235-243.
[24] Wegner L, Anthonsen S, Bork-Jensen J, Dal-
gaard L, Hansen T, Pedersen O, Poulsen P and 
Vaag A. LMNA rs4641 and the muscle lamin A 
and C isoforms in twins--metabolic implica-
tions and transcriptional regulation. J Clin En-
docrinol Metab 2010; 95: 3884-3892.
[25] Haithcock E, Dayani Y, Neufeld E, Zahand AJ, 
Feinstein N, Mattout A, Gruenbaum Y and Liu 
J. Age-related changes of nuclear architecture 
in Caenorhabditis elegans. Proc Natl Acad Sci 
U S A 2005; 102: 16690-16695.
[26] Porensky PN, Mitrpant C, McGovern VL, Bevan 
AK, Foust KD, Kaspar BK, Wilton SD and Bur-
ghes AH. A single administration of morpholino 
antisense oligomer rescues spinal muscular 
atrophy in mouse. Hum Mol Genet 2012; 21: 
1625-1638.
